Group 1 - The company China Financial International (00721) announced that as of January 31, 2026, the unaudited net asset value per ordinary share is approximately HKD 0.02 [1]

2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中OSL集团(00863) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，OSL集团有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 OSL集团此前公告，本集团预期于2025财年(截至2025年12月31日止年度)取得持续经营业务的净亏损介 乎约3.7亿港元至4.3亿港元，而截至2024年12月31日止年度(2024财年)则取得持续经营业务的溢利约 5500万港元，原因是本集团作出重要投资以奠定未来增长的稳健基础。 ...

康臣药业此前公告，于2025年6月13日，董事局决议执行股份回购计划，以资金总数不超过2亿港元为 限，于公开市场适时回购股份(先前股份回购计划)。于2026年1月29日，董事局决议根据购回授权进一 步执行另一项股份回购计划，以于公开市场适时回购股份，除先前股份回购计划的资金总数外，额外增 加最多1亿港元(股份回购计划)。据此股份回购计划合计拟动用资金总额将不超过3亿港元。股份回购计 划之期限自本公告日期起至公司下届股东周年大会结束时止或股东于股东大会上撤回或修订购回授权为 止。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中康臣药业(01681) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，康臣药业有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

Core Viewpoint - The company, CNOOC Engineering (600583.SH), has received a bid notification from QatarEnergy LNG, confirming its selection as the winning bidder for the "NFPSCOMP5" project, in partnership with Saipem, with a total contract value of approximately $4 billion, of which the company's share exceeds $800 million [1] Group 1: Project Details - The project is part of the company's main business operations [1] - The total contract amount is approximately $4 billion [1] - The company's share of the contract is over $800 million [1] Group 2: Strategic Implications - Winning this project signifies further recognition of the company's comprehensive strength in the mainstream oil and gas market in the Middle East [1] - Successful signing and implementation of the project will positively impact the company's performance and promote future business development [1] - This achievement supports the company's "14th Five-Year" overseas strategic plan and exemplifies its commitment to the Belt and Road Initiative, facilitating deeper participation of Chinese enterprises in international energy cooperation [1]

Group 1 - The core point of the article is that Shanghai Zhida Technology Development Co., Ltd. (H-share 02650) has been included in the Hang Seng Composite Index, effective after the market closes on March 6, 2026, and officially starting on March 9, 2026 [1] - The inclusion in the Hang Seng Composite Index is expected to enhance the company's visibility and liquidity in the market, as it will attract more passive fund allocations [1] - The adjustment will also lead to a simultaneous update of the Hong Kong Stock Connect eligible stocks, allowing Zhida Technology to enter the Hong Kong Stock Connect on the same day [1]

京东工业2025年12月11日在港交所挂牌上市，该公司是中国领先的工业供应链技术与服务提供商。通过 践行变革性的工业供应链数智化转型，帮助客户实现保供、降本、增效及合规。该公司于2017年开始布 局专注于MRO采购服务的供应链技术与服务业务。经过多年发展，已成为中国MRO采购服务市场的最 大参与者，根据灼识咨询的资料显示，按2024 年的交易额计，该公司排名第一，规模为第二名的近三 倍。根据同一资料显示，随着该公司向更广阔的工业供应链市场扩展，按2024年的交易额计，该公司亦 为中国工业供应链技术与服务市场最大的服务提供商，市场份额达到4.1%。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中京东工业(07618) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，京东工业有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

董事会认为，公司获纳入恒生综合指数及上述指数的成份股反映市场对集团的积极业务表现、投资价值 及发展潜力的进一步认可。预期公司的公众知名度将得到提升， H股的交易流动性亦将得到改善，从而 为集团提供更多业务发展及合作可能性。 迅策(03317)公布，公司已获恒生指数有限公司选择及将被纳入下列指数的成份股：恒生综合指数、恒 生综合行业指数 — 资讯科技业、恒生综合中小型股指数、恒生综合小型股指数、恒生资讯科技业(可投 资)指数、恒生港股通资讯科技业指数、恒生港股通软件主题指数 、恒生港股通软件及半导体指数，自 2026年3月9日起生效。 ...

Group 1 - The core announcement is that Jiaxin International Resources (03858) will be included in the Hang Seng Composite Index, with changes effective from March 9, 2026 [1] - The inclusion is based on meeting criteria such as market capitalization, liquidity, and listing duration, which may also lead to its eligibility for the Stock Connect program [1] - Jiaxin International Resources anticipates a turnaround from a loss of HKD 173 million for the year ending December 31, 2024, to a profit of approximately HKD 300 million to HKD 340 million for the year ending December 31, 2025 [1] Group 2 - The expected profit turnaround is attributed to the fact that the group did not generate any revenue in 2024 as it had not commenced operations [1] - Commercial production is set to begin in April 2025, marking the start of revenue generation and the transition to profitability [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Weisheng Holdings (03393) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Weisheng Holdings is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Weisheng Holdings has submitted a proposal for a spin-off to the Hong Kong Stock Exchange in accordance with Listing Rule Guidance No. 15, and the exchange has confirmed that the company can proceed with the proposed spin-off [1] - On January 27, 2026, Weiyuan Energy submitted a listing application form (Form A1) to the Hong Kong Stock Exchange through its exclusive sponsor, seeking to list and trade its shares on the main board of the exchange [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Pagoda Biopharma-B (02565) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Pagoda Biopharma is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Pagoda Biopharma previously announced that all conditions of the placement agreement had been met, with the placement completed on December 22, 2025 [1] - Under the terms of the placement agreement, the joint placement agents sold a total of 5.136 million shares at a price of HKD 58.41 per share to no fewer than six subscribers, representing approximately 1.81% of the enlarged H-shares and about 1.31% of the total shares after the placement [1]